Page last updated: 2024-11-05

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Osteogenic Sarcoma

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Osteogenic Sarcoma in 2 studies

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
He, G1
Pan, X1
Liu, X2
Zhu, Y1
Ma, Y1
Du, C1
Mao, C1
Liang, D1
Yang, M1
Guo, B1
Yang, L1
Cao, J1
Zhang, X1

Other Studies

2 other studies available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Osteogenic Sarcoma

ArticleYear
HIF-1α-Mediated Mitophagy Determines ZnO Nanoparticle-Induced Human Osteosarcoma Cell Death both In Vitro and In Vivo.
    ACS applied materials & interfaces, 2020, Oct-28, Volume: 12, Issue:43

    Topics: Antineoplastic Agents; Bone Neoplasms; Cell Death; Cell Proliferation; Drug Screening Assays, Antitu

2020
HIF-1α induced by β-elemene protects human osteosarcoma cells from undergoing apoptosis.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:11

    Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Dose-R

2012